BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors
U.S. Securities and Exchange Commission, University of California, San Diego Performance-Based Skills Assessment, Degenerative disc disease, Pain, Securities Act of 1933, San Diego State University, Stem cell, GLOBE, Securities Exchange Act of 1934, Cardiology, MBA, Human, Security (finance), Private Securities Litigation Reform Act, Glucose, Food, Company, Bone marrow, Epilepsy, Animal, Neuro, Industry, Rosa, BAT, Dystonia, Obesity, Callaway Golf Company, Risk, N. K. Venkataramana, Leadership, NMTC, B cell, Food and Drug Administration, OTC, Kyocera Communications, Growth, Lists of diseases, Diabetes, Zeltiq Aesthetics, St. Jude Medical, Nasdaq, EEG, NuVasive, Board of directors, University, Institut de Finance et Management, STAAR, Patient, General manager, Allergan, Adult, Board, Chronic pain, Cell, Form 10-K, Management, Pharmaceutical industry
Their election to the Board will take effect in the event the Companys pending registration statement becomes effective.
Key Points:
- Their election to the Board will take effect in the event the Companys pending registration statement becomes effective.
- Our new board member nominations represent qualified and diverse executives who bring new perspectives, relevant expertise and leadership experience, positioning BioRestorative to fulfill our mission of bringing cell therapies to patients said Lance Alstodt, Chief Executive Officer of BioRestorative.
- Patrick F. Williams has more than 20 years of experience across medical device, consumer product goods and technology sectors.
- BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.